PPT-Daclatasvir - Asunaprevir

Author : queenie | Published Date : 2022-06-28

Beclabuvir in GT1 Patients without Cirrhosis UNITY1 Study Phase 3 Treatment Naïve and TreatmentExperienced Poordad F et al JAMA 2015313172835 Source Poordad

Presentation Embed Code

Download Presentation

Download Presentation The PPT/PDF document "Daclatasvir - Asunaprevir" is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.

Daclatasvir - Asunaprevir: Transcript

Beclabuvir in GT1 Patients without Cirrhosis UNITY1 Study Phase 3 Treatment Naïve and TreatmentExperienced Poordad F et al JAMA 2015313172835 Source Poordad F et al JAMA 2015313172835. + Sofosbuvir in HCV GT 1-4 and HIV Coinfection. ALLY-2 Study. Phase 3. . Treatment. -. Naïve . and . Treatment-Experienced. Wyles. DL, . et al. . N . Engl. J Med. 2015;373:714-25.. Source: . Wyles. . + . Sofosbuvir. in Genotype . 3. ALLY-3 Study. Phase 3. . Treatment. -. Naïve . and . Treatment-Experienced. Nelson DR, . et al. . . Hepatology. 2015;61:1127-35.. Source: . Nelson DR, et al. . With Or Without Ribavirin Is Safe and Efficacious in Liver Transplant Recipients With HCV Recurrence: . Interim Results of a European Multicenter Compassionate Use Program. Herzer K,. 1. . Welzel. . + Sofosbuvir in HCV GT 1-4 and HIV Coinfection. ALLY-2 Study. Phase 3. . Treatment. -. Naïve . and . Treatment-Experienced. Wyles DL, . et al. . N Engl J Med. 2015;373:714-25.. Source: Wyles DL, et al. N Engl J Med. 2015;373:714-25.. With Or Without Ribavirin Is Safe and Efficacious in Liver Transplant Recipients With HCV Recurrence: . Interim Results of a European Multicenter Compassionate Use Program. Herzer K,. 1. . Welzel. . W24. DCV + PR. Placebo + PR. Yes. Dore GJ. Gastroenterology 2015;148:355-66 . COMMAND GT2/3. COMMAND GT2/3 Study: . daclatasvir. + PEG-IFN . + RBV for genotype 2 or 3. DCV + PEG-IFN + RBV. N = 50. No. Interim Analysis of a French Multicenter Compassionate Use Program. Christophe Hézode,. 1. Victor De Ledinghen,. 2. Helene Fontaine,. 3. Fabien Zoulim,. 4. Pascal Lebray,. 5. Nathalie Boyer,. 6. University of Chicago. Chicago, Illinois. Challenges in the Management and Treatment of HIV/Hepatitis C Virus Coinfection. FORMATTED: 05/02/2016. Chicago, Illinois: May 9, 2016. From . AI . Aronsohn. . with Advanced Liver Disease. ALLY-3+ Study. Phase 3. . Treatment. -. Naïve . and . Treatment-Experienced. Leroy V, . et al. . Hepatology 2016;63:1430-41.. Source: Leroy V, et al. Hepatology . 2016;63:1430-41.. . Plus . Sofosbuvir. With or Without Ribavirin . for the Treatment of Chronic HCV . Genotype . 3 Infection: . Interim Results of a Multicenter . European Compassionate . Use . Program. Welzel. TM,.

Download Document

Here is the link to download the presentation.
"Daclatasvir - Asunaprevir"The content belongs to its owner. You may download and print it for personal use, without modification, and keep all copyright notices. By downloading, you agree to these terms.